Author

C. J. Ott

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:chromatin & epigenetic regulation· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

A. Abbasi· 1 shared A. D. Viny· 1 shared A. Kumar· 1 shared A. Langenbucher· 1 shared A. N. Hata· 1 shared A. N. Koehler· 1 shared A. Navitski· 1 shared A. R. Ramos· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Abbasi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Targeted Degradation of CDK9 Potently Disrupts the MYC Transcriptional Network

M. A. Toure, K. Motoyama, Y. Xiang, J. Urgiles, F. Kabinger, A.-S. Koglin, R. S. Iyer, K. Gagnon, A. Kumar, S. Ojeda, D. A. Harrison, M. G. Rees, J. A. Roth, C. J. Ott, R. Schiavoni, , A. N. Koehler

This study shows that CDK9 degradation with KI-CDK9d-32 is more effective than inhibition in disrupting MYC transcriptional networks and causes MYC downregulation and nucleolar destabilization.

bioRxiv · May 14, 2024 · PreprintCancer Biology

Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities

Y. Zhang, D. Remillard, U. Onubogu, B. Karakyriakou, J. N. Asiaban, A. R. Ramos, K. Bowland, T. R. Bishop, C. J. Ott, M. Janiszewska, B. F. Cravatt, M. A. Erb

The paper identifies collateral synthetic lethality between HDAC1 and HDAC2 in cancer cells and shows that targeting HDAC2 can suppress tumor growth by disrupting the NuRD complex.

bioRxiv · May 30, 2022Cancer Biology

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

H. Isozaki, A. Abbasi, N. Nikpour, A. Langenbucher, W. Su, M. Stanzione, H. Frisco-Cabanos, F. M. Siddiqui, N. Phan, P. Jalili, S. Oh, D. Timonina, S. Bilton, M. Gomez-Caraballo, H. L. Archibald, , A. N. Hata

This study shows that APOBEC3A mutagenesis driven by targeted therapies promotes drug resistance in non-small cell lung cancer.

bioRxiv · Jan 20, 2021Cancer Biology

Stag1 and Stag2 regulate cell fate decisions in hematopoiesis through non-redundant topological control

A. D. Viny, R. L. Bowman, Y. Liu, V.-P. Lavallee, S. E. Redlich, W. Xiao, B. H. Durham, A. Navitski, J. Park, S. Braunstein, E. Azizi, M. Witkin, T. Baslan, C. J. Ott, D. Pe'er, , R. L. Levine

The paper shows Stag2 loss in HSPCs impairs B-cell lineage commitment by reducing chromatin accessibility, while Stag1 cannot restore this function despite rescuing topological domains.

bioRxiv · Mar 18, 2019 · PreprintCell Biology